Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-06-26

Clinical Trial Update: Low Dose Naltrexone for Glioma Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating low-dose naltrexone in malignant glioma has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Naltrexone (Naltrexone)

Snippet

Sponsor: Katy Peters | Conditions: Malignant Glioma | Phase 2 | Status: COMPLETED | Results posted: 2015-06-26